EGRX has been the subject of a number of other research reports. Royal Bank of Canada reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Eagle Pharmaceuticals in a research note on Sunday, August 11th. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 17th. TheStreet downgraded shares of Eagle Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 22nd. Finally, ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Eagle Pharmaceuticals has an average rating of “Hold” and an average price target of $60.25.
EGRX stock opened at $56.90 on Wednesday. Eagle Pharmaceuticals has a one year low of $36.03 and a one year high of $64.94. The firm has a 50-day moving average of $60.13 and a two-hundred day moving average of $56.66. The firm has a market capitalization of $777.82 million, a PE ratio of 27.22 and a beta of 1.40. The company has a current ratio of 4.24, a quick ratio of 4.07 and a debt-to-equity ratio of 0.20.
In other Eagle Pharmaceuticals news, Director Hudson Executive Capital Lp sold 1,112 shares of Eagle Pharmaceuticals stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $60.06, for a total transaction of $66,786.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 51,179 shares of company stock valued at $3,184,071 over the last 90 days. Corporate insiders own 31.70% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Wedge Capital Management L L P NC acquired a new position in shares of Eagle Pharmaceuticals in the third quarter worth $268,000. Louisiana State Employees Retirement System acquired a new stake in Eagle Pharmaceuticals during the second quarter valued at $206,000. Charles Schwab Investment Management Inc. boosted its position in Eagle Pharmaceuticals by 14.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 111,946 shares of the specialty pharmaceutical company’s stock valued at $6,234,000 after purchasing an additional 14,111 shares during the last quarter. Systematic Financial Management LP purchased a new position in Eagle Pharmaceuticals in the second quarter valued at about $931,000. Finally, First Quadrant L P CA purchased a new position in Eagle Pharmaceuticals in the second quarter valued at about $34,000. Hedge funds and other institutional investors own 95.25% of the company’s stock.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.